LAM-001

DRUG2 trials

Sponsors

OrphAI Therapeutics, Steven Hays, MD

Conditions

Bronchiolitis Obliterans SyndromeChronic Lung Allograft DysfunctionLung TransplantationPulmonary Hypertension Due to Lung Diseases and Hypoxia

Phase 2

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

RecruitingNCT05798923

OrphAI TherapeuticsPulmonary Hypertension Due to Lung Diseases and Hypoxia

Start: 2023-08-30End: 2028-08-30Target: 85Updated: 2026-08-03

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

RecruitingNCT06018766

Steven Hays, MDBronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation

Start: 2023-08-17End: 2026-12-01Target: 30Updated: 2026-05-18